INS and type 1 diabetes mellitus: While potential therapeutic options to postpone or prevent T1D are emerging, with most notably the Food and Drug Administration approval of teplizumab (an anti-CD3 monoclonal antibody),45 46 there is still much to be done in this area, as there are no known therapeutic options available for CPI-D aside from insulin administration.